A detailed history of Assenagon Asset Management S.A. transactions in Veracyte, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 29,455 shares of VCYT stock, worth $1.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,455
Previous 12,943 127.57%
Holding current value
$1.28 Million
Previous $280,000 257.86%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$21.0 - $35.25 $346,752 - $582,048
16,512 Added 127.57%
29,455 $1 Million
Q4 2023

Jan 17, 2024

SELL
$19.72 - $28.68 $1.06 Million - $1.54 Million
-53,713 Reduced 80.58%
12,943 $356,000
Q3 2023

Nov 06, 2023

SELL
$22.33 - $29.92 $631,313 - $845,898
-28,272 Reduced 29.78%
66,656 $1.49 Million
Q2 2023

Jul 25, 2023

BUY
$20.96 - $26.99 $863,866 - $1.11 Million
41,215 Added 76.73%
94,928 $2.42 Million
Q4 2022

Jan 12, 2023

BUY
$15.31 - $29.94 $822,346 - $1.61 Million
53,713 New
53,713 $1.28 Million
Q2 2022

Jul 27, 2022

BUY
$15.45 - $29.52 $1.87 Million - $3.57 Million
121,075 New
121,075 $2.41 Million
Q1 2022

Apr 25, 2022

SELL
$21.94 - $42.51 $112,574 - $218,118
-5,131 Closed
0 $0
Q4 2021

Feb 01, 2022

BUY
$36.09 - $53.79 $185,177 - $275,996
5,131 New
5,131 $211,000
Q1 2020

Apr 17, 2020

SELL
$16.13 - $30.17 $553,226 - $1.03 Million
-34,298 Closed
0 $0
Q4 2019

Jan 17, 2020

BUY
$20.78 - $29.99 $712,712 - $1.03 Million
34,298 New
34,298 $958,000
Q2 2019

Aug 12, 2019

SELL
$22.1 - $28.56 $7.63 Million - $9.86 Million
-345,118 Closed
0 $0
Q1 2019

Apr 26, 2019

SELL
$12.0 - $25.76 $10.5 Million - $22.4 Million
-871,012 Reduced 71.62%
345,118 $8.64 Million
Q4 2018

Jan 23, 2019

BUY
$9.15 - $14.85 $11.1 Million - $18.1 Million
1,216,130 New
1,216,130 $15.3 Million

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $3.11B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.